Insider Transactions in Q4 2025 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-5.39%
|
$1,590,000
$53.98 P/Share
|
|
Oct 10
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+5.12%
|
$570,000
$19.87 P/Share
|
|
Oct 08
2025
|
G. Walmsley Graham |
BUY
Exercise of conversion of derivative security
|
Direct |
90,832
+25.76%
|
$1,816,640
$20.53 P/Share
|
|
Oct 08
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
52,212
+9.03%
|
$0
$0.62 P/Share
|
|
Oct 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.51%
|
$575,000
$46.41 P/Share
|
|
Oct 07
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.53%
|
$350,000
$28.35 P/Share
|
|
Oct 01
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.03%
|
$587,500
$47.81 P/Share
|
|
Oct 01
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.63%
|
$262,500
$21.1 P/Share
|